Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib combined with aromatase inhibitors for breast cancer
ISRCTN18026884Phase 2Completed
- Sponsor
- First Hospital of China Medical University
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib, exemestane, letrozole and anastrozole in breast cancer, sponsored by First Hospital of China Medical University. Primary endpoint: Objective response rate. Started Jan 2023; status: completed.
02
Drugs
palbociclibexemestaneletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN18026884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18026884.